slide1 l.
Skip this Video
Loading SlideShow in 5 Seconds..
Adult Immunization 2010 Meningococcal Vaccine Segment PowerPoint Presentation
Download Presentation
Adult Immunization 2010 Meningococcal Vaccine Segment

Loading in 2 Seconds...

play fullscreen
1 / 13

Adult Immunization 2010 Meningococcal Vaccine Segment - PowerPoint PPT Presentation

  • Uploaded on

Adult Immunization 2010 Meningococcal Vaccine Segment. This material is in the public domain This information is valid as of May 25, 2010. Meningococcal Polysaccharide Vaccine (MPSV) - Menomune. Quadrivalent (serogroups A, C, Y, W-135) Approved for persons 2 years of age and older

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about 'Adult Immunization 2010 Meningococcal Vaccine Segment' - kamana

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Adult Immunization 2010

Meningococcal Vaccine Segment

This material is in the public domain

This information is valid as of May 25, 2010

meningococcal polysaccharide vaccine mpsv menomune
Meningococcal PolysaccharideVaccine (MPSV) - Menomune
  • Quadrivalent (serogroups A, C, Y, W-135)
  • Approved for persons 2 years of age and older
  • Administered by subcutaneous injection
mpsv recommendations
MPSV Recommendations
  • Not recommended for routine vaccination of civilians
  • Should be used only for persons at increased risk of infection who are 56 years of age or older, or if meningococcal conjugate vaccine is not available
meningococcal conjugate vaccine mcv
Meningococcal ConjugateVaccine (MCV)
  • Quadrivalent (serogroups A, C, Y, W-135) conjugated to diphtheria toxoid
  • Menactra approved for persons 2 through 55 years of age
  • Menveo approved for persons 11 through 55 years of age
  • Administered by intramuscular injection
meningococcal vaccine recommendations
Meningococcal Vaccine Recommendations
  • Use of MCV is preferred for persons 2 through 55 years of age for whom meningococcal vaccine is recommended
  • Meningococcal vaccination is routinely recommended for
    • adolescents
    • college freshmen who live in a dormitory
    • adults at increased risk of infection

MMWR 2005;54(RR-7)

meningococcal vaccine recommendations6
Meningococcal VaccineRecommendations
  • Recommended for certain high- risk persons:
    • persistent complement component deficiency
    • HIV infection
    • functional or anatomic asplenia
    • military recruits
    • certain research and laboratory personnel
    • travelers to and U.S. citizens residing in countries in which N. meningitidis is hyperendemic or epidemic

MMWR 2005;54(RR-7)

meningococcal vaccine revaccination
Meningococcal VaccineRevaccination
  • Persons through age 55 years who received a previous dose of meningococcal conjugate or meningococcal polysaccharide vaccine and remain at increased risk should receive an additional dose of meningococcal conjugate five years after the previous dose

MMWR 2009;58(37):1042-3

meningococcal vaccine revaccination8
Meningococcal VaccineRevaccination
  • High-risk groups who should be revaccinated
    • persistent complement component deficiency
    • persons with anatomic or functional asplenia
    • microbiologists with prolonged exposure to Neisseria meningitidis
    • frequent travelers to or persons living in areas with high rates of meningococcal disease

MMWR 2009;58(37):1042-3

meningococcal vaccine revaccination9
Meningococcal VaccineRevaccination
  • Revaccination with meningococcal conjugate vaccine is currently not recommended for persons whose only risk factor is living in on-campus housing (i.e., a college student living in a dormitory)

MMWR 2009;58(37):1042-3

meningococcal vaccine contraindications and precautions
Meningococcal Vaccine Contraindications and Precautions
  • Severe allergic reaction to a vaccine component or following a prior dose
  • Moderate or severe acute illness

MMWR 2005;54(RR-7)

meningococcal vaccines adverse reactions
Meningococcal VaccinesAdverse Reactions
  • Local reactions 3%-29% 11%-59%

for 1-2 days

  • Low grade fever 3% 5%
  • Systemic reactions 8%-29% 11%-36%

(headache, malaise




MMWR 2005;54(RR-7)

mcv and guillain barre syndrome
MCV and Guillain-Barre’ Syndrome
  • GBS is a rare illness and expected background incidence rates are not precisely known
  • The number of reports is similar to the number of cases expected to occur in this age group
  • Since 2007, ACIP has considered a history of GBS to be a precaution to the use of meningococcal conjugate vaccine
  • Meningococcal polysaccharide is an acceptable alternative to MCV
  • ACIP is reconsidering this issue
national center for immunization and respiratory diseases contact information
National Center for Immunization and Respiratory DiseasesContact Information
  • Telephone (800) CDC-INFO
  • Email
  • Website
  • Broadcast Updates and Resources

Web Page